<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Denosumab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Denosumab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Denosumab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="15576" href="/d/html/15576.html" rel="external">see "Denosumab: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="110538" href="/d/html/110538.html" rel="external">see "Denosumab: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F57513194"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Risk of Severe Hypocalcemia in Patients on Dialysis: Safety Alert</span>
<span class="collapsible-date">January 2024</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA is adding a Boxed Warning to the Prolia (denosumab) prescribing information concerning the significant risk of developing severe hypocalcemia in patients with advanced chronic kidney disease (CKD), particularly patients on dialysis. Severe hypocalcemia appears to be more common in patients with CKD who also have mineral and bone disorder. In patients with advanced CKD taking Prolia, severe hypocalcemia resulted in serious harm, including hospitalization, life-threatening events, and death. Severe hypocalcemia can be asymptomatic or may present as confusion; seizures; arrhythmias; fainting; face twitching; uncontrolled muscle spasms; or weakness, tingling, or numbness in parts of the body. In addition to the Boxed Warning, the prescribing information will be updated to include information on how to reduce the risk of hypocalcemia, including appropriate patient selection for Prolia treatment, monitoring of calcium levels, and other strategies. The updated safety information will also be incorporated into the Medication Guide and the Prolia Risk Evaluation and Mitigation Strategy (REMS).</p>
<p style="text-indent:0em;">Further information can be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-adds-boxed-warning-increased-risk-severe-hypocalcemia-patients-advanced-chronic-kidney-disease&amp;token=6pfL%2FyPHxlUTCJz2wuTiF43JxRhsYtMsvCcXcApD3u5XamBBl3o0vxksU5eOQQYoaSO%2FclzorKqFvBe8M3H%2B2FGjb%2FIwdJOK4RDj72z%2FN2Xde67yFuHNU46csEzcyeP%2BVRDlI4nVpx6MPNg4aVTW5YFvSic2Czjzxgvm5X7GcCo%3D&amp;TOPIC_ID=15575" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-boxed-warning-increased-risk-severe-hypocalcemia-patients-advanced-chronic-kidney-disease</a></p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F10267890"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Prolia;</li>
<li>Xgeva</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871174"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Prolia;</li>
<li>Xgeva</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F10267529"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Bone-Modifying Agent;</li>
<li>
                        Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F10267929"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Correct hypocalcemia and vitamin D deficiency (eg, to a 25-hydroxyvitamin D level ≥20 ng/mL [≥50 nmol/L]), when appropriate, before initiation, and ensure adequate calcium and vitamin D intake during therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30907953','lexi-content-ref-34448749','lexi-content-ref-Rosen.2','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30907953','lexi-content-ref-34448749','lexi-content-ref-Rosen.2','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="86d18d33-04ac-4384-a834-acfd42b29e09">Bone metastases from solid tumors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bone metastases from solid tumors (prevention of skeletal-related events; Xgeva):</b>
<b>SUBQ:</b> 120 mg every 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21353695','lexi-content-ref-21343556','lexi-content-ref-21060033']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21353695','lexi-content-ref-21343556','lexi-content-ref-21060033'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="94e5e075-2d72-49e0-968f-970352b39798">Giant cell tumor of bone</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Giant cell tumor of bone (Xgeva): SUBQ:</b> 120 mg once every 4 weeks; during the first month, give an additional 120 mg on days 8 and 15 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Blay.2011','lexi-content-ref-20149736']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Blay.2011','lexi-content-ref-20149736'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d651d917-5b3e-4644-84f8-f0afb2d722ca">Hypercalcemia of malignancy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypercalcemia of malignancy (albumin-corrected serum calcium ≥12 mg/dL [≥3 mmol/L]) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in patients with hypercalcemia that is refractory to bisphosphonates, or in patients in whom bisphosphonates cannot be taken. Asymptomatic or mildly symptomatic patients with chronic hypercalcemia may not require immediate treatment unless albumin-corrected serum calcium level is &gt;14 mg/dL (&gt;3.5 mmol/L) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Shane.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Shane.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ (Xgeva): </b>120 mg once weekly for up to 3 doses; if the cause of hypercalcemia persists, may continue at 120 mg every 4 weeks starting 2 weeks after the initial 3 weekly doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24915117','lexi-content-ref-Shane.2022','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24915117','lexi-content-ref-Shane.2022','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> In patients with contraindications to bisphosphonates (eg, severe kidney impairment, bisphosphonate allergy), some experts administer a single dose of 60 mg; monitor carefully in patients with kidney impairment due to high risk of hypocalcemia in this setting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34515963','lexi-content-ref-22711097','lexi-content-ref-Shane.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34515963','lexi-content-ref-22711097','lexi-content-ref-Shane.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a4f575b1-9ab5-4ea5-b16e-1724f4fcbc62">Multiple myeloma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma (prevention of skeletal-related events; Xgeva):</b>
<b>SUBQ:</b> 120 mg every 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29429912']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29429912'])">Ref</a></span>). Denosumab has a reversible mechanism of action and therefore should not be discontinued abruptly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29341831']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29341831'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cbb62208-a939-4266-af5a-cbebe2eb2458">Osteoporosis/bone loss</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis/bone loss (Prolia):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Androgen deprivation therapy-induced bone loss in males with prostate cancer, treatment: SUBQ:</b> 60 mg once every 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19671656']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19671656'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Aromatase inhibitor-induced bone loss in females with breast cancer, treatment:</b>
<b>SUBQ:</b> 60 mg once every 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18725648']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18725648'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Osteoporosis, fracture risk reduction (males and postmenopausal females) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For use in patients in whom first-line therapies are ineffective or cannot be used, <b>or</b> as an alternative antiresorptive agent following anabolic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30907953','lexi-content-ref-Rosen.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30907953','lexi-content-ref-Rosen.2'])">Ref</a></span>). Therapy following discontinuation must be well-coordinated; avoid use in patients who have difficulty adhering to medication or appointment schedules (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33103722','lexi-content-ref-Rosen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33103722','lexi-content-ref-Rosen.1'])">Ref</a></span>). Prior to use, evaluate and treat any potential causes of secondary osteoporosis (eg, severe vitamin D deficiency) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25182228'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>SUBQ:</b> 60 mg once every 6 months.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Duration of therapy:</b> The optimal duration of therapy has not been established. If fracture risk remains high after 5 to 10 years of therapy, consider extending therapy or switching to alternative therapy (eg, a bisphosphonate); there are no data on use beyond 10 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32427503','lexi-content-ref-33103722','lexi-content-ref-30907953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32427503','lexi-content-ref-33103722','lexi-content-ref-30907953'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Discontinuation/interruption of therapy:</b> Discontinuation or interruption (eg, &gt;1 month beyond next scheduled dose) of denosumab should not occur without subsequent antiresorptive therapy (eg, with a bisphosphonate) due to increased risk of vertebral fracture; drug holidays are not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32427503','lexi-content-ref-33103722','lexi-content-ref-30907953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32427503','lexi-content-ref-33103722','lexi-content-ref-30907953'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Missed dose:</b> If a dose is missed, administer as soon as possible; fracture risk may be increased if dose is not administered within 7 months of prior dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32427503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32427503'])">Ref</a></span>). Thereafter, schedule doses every 6 months from the date of the last injection.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Osteoporosis, glucocorticoid-induced (males and females):</b>
<b>SUBQ:</b> 60 mg once every 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29631782']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29631782'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b18a47be-ee08-4931-a81c-bca6cf0708e7">Bone destruction caused by rheumatoid arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bone destruction caused by rheumatoid arthritis (off-label use; based on limited data): SUBQ:</b> 60 mg or 180 mg as a single dose and repeated at 6 months (in combination with continued methotrexate); a total of 2 doses was administered in the study (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18438830']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18438830'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991057"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Monitor patients with severe impairment (CrCl &lt;30 mL/minute or on dialysis) closely, as significant and prolonged hypocalcemia (incidence of 29% and potentially lasting weeks to months) and marked elevations of serum parathyroid hormone are serious risks in this population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31016056','lexi-content-ref-30519493','lexi-content-ref-30405927','lexi-content-ref-26466702','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31016056','lexi-content-ref-30519493','lexi-content-ref-30405927','lexi-content-ref-26466702','lexi-content-ref-Manu.1'])">Ref</a></span>). Ensure adequate calcium and vitamin D intake/supplementation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute:</p>
<p style="text-indent:-2em;margin-left:6em;">Prolia: No dosage adjustment necessary; use in conjunction with guidance from patient's nephrology team, as osteoporosis is difficult to distinguish from chronic kidney disease mineral and bone disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Export.DOR'])">Ref</a></span>). The risk of Prolia administration must be weighed against the accuracy of the diagnosis of the underlying bone disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30675420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30675420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Xgeva: There are no specific dosage adjustments recommended. Guidelines suggest dosage adjustment is not necessary; close monitoring for hypocalcemia is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29341831','lexi-content-ref-29035643','lexi-content-ref-27896639']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29341831','lexi-content-ref-29035643','lexi-content-ref-27896639'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be removed by hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bailie.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bailie.2020'])">Ref</a></span>); dose as for patients with CrCl &lt;30 mL/minute; use with caution and monitor calcium levels closely, with appropriate adjustment in dialysate calcium concentration in addition to adequate calcium and active vitamin D supplementation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29713798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29713798'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be removed by peritoneal dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bailie.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bailie.2020'])">Ref</a></span>); dose as for patients with CrCl &lt;30 mL/minute; use with caution and monitor calcium levels closely.</p></div>
<div class="block doha drugH1Div" id="F50988302"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F10267930"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F20707398"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="110538" href="/d/html/110538.html" rel="external">see "Denosumab: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Administer calcium and vitamin D as necessary to prevent or treat hypocalcemia.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="710c6916-80d3-4b00-988e-6e49d8772b08">Giant cell tumor of the bone, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Giant cell tumor of the bone, treatment:</b> Xgeva: Adolescents (skeletally mature) weighing ≥45 kg: SubQ: 120 mg once every 4 weeks; during the first month, give an additional dose of 120 mg on days 8 and 15 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23867211','lexi-content-ref-20149736']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23867211','lexi-content-ref-20149736'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51093602"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Monitor patients with severe impairment (CrCl &lt;30 mL/minute or on dialysis) due to increased risk of hypocalcemia.</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:0em;">Xgeva: There are no dosage adjustments provided in the manufacturer's labeling; however, in studies of patients with varying degrees of renal impairment, the degree of renal impairment had no effect on denosumab pharmacokinetics or pharmacodynamics.</p></div>
<div class="block dohp drugH1Div" id="F51093603"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F55183676"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Fracture</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Atypical<b> femur fracture</b> (AFF) has been reported in patients receiving denosumab for both treatment of osteoporosis as well as in cancer settings (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32642421','lexi-content-ref-31640606','lexi-content-ref-28275116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32642421','lexi-content-ref-31640606','lexi-content-ref-28275116'])">Ref</a></span>). The fractures may occur anywhere along the femoral shaft (may be bilateral) and commonly occur with minimal to no trauma to the area. Some patients experience prodromal thigh or groin pain weeks or months before the fracture occurs. Contralateral limb should be assessed if AFF occurs. Multiple <b>vertebral column fracture</b> has been reported following discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32373677','lexi-content-ref-32487552','lexi-content-ref-31193884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32373677','lexi-content-ref-32487552','lexi-content-ref-31193884'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Time-related; exact mechanism is not fully understood (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23712442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23712442'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>AFF</i>: AFF are considered stress or insufficiency fractures that develop over time. Antiresorptive agents, including denosumab, suppress bone remodeling which results in increased skeletal fragility and may allow stress fractures to grow to critical size (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23712442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23712442'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Multiple vertebral column fracture</i>: Discontinuation of therapy results in a rapid, profound increase of bone resorption and loss of bone mineral density, which has been associated with increased risk of rebound-associated multiple vertebral fractures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32373677','lexi-content-ref-32487552']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32373677','lexi-content-ref-32487552'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Delayed; according to the manufacturer, multiple vertebral column fracture has been reported an average of 17 months (range: 7 months to 43 months) after the last dose. Similarly, a few studies report a range of 8 months to 16 months after the last dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32373677','lexi-content-ref-32487552','lexi-content-ref-31193884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32373677','lexi-content-ref-32487552','lexi-content-ref-31193884'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>AFF:</i></p>
<p style="text-indent:-2em;margin-left:8em;">• Duration of therapy; in general, long durations (eg, &gt;5 years) of antiresorptive medications are associated with an increased risk of AFF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29951870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29951870'])">Ref</a></span>). The duration of denosumab therapy associated with an increased risk has not been fully elucidated; treatment up to 10 years continues to be associated with a favorable skeletal benefit/risk profile (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32092479']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32092479'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Prior history of AFF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29675745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29675745'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Patients of Asian descent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29339529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29339529'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bowed femora (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29339529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29339529'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Varus femoral neck/shaft angle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29339529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29339529'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Presence of prodromal symptoms (eg, thigh or groin pain) or signs of early fracture line or periosteal reaction on image of femur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29339529','lexi-content-ref-27802096','lexi-content-ref-22451554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29339529','lexi-content-ref-27802096','lexi-content-ref-22451554'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent use of glucocorticoids for &gt;6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29339529','lexi-content-ref-23712442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29339529','lexi-content-ref-23712442'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Prior long-term use of oral or IV bisphosphonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26501556','lexi-content-ref-31640606']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26501556','lexi-content-ref-31640606'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Active rheumatoid arthritis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23712442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23712442'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29675745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29675745'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Low serum hydroxyl-vitamin D concentrations (eg, &lt;16 ng/mL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23712442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23712442'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Vertebral column fracture:</i></p>
<p style="text-indent:-2em;margin-left:8em;">• Prior history of vertebral fracture</p>
<p style="text-indent:-2em;margin-left:8em;">• Discontinuation of therapy</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypocalcemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Denosumab may cause or exacerbate <b>hypocalcemia</b>; <b>severe hypocalcemia</b> (symptomatic cases, including fatalities) has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28382583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28382583'])">Ref</a></span>). Patients may experience a single hypocalcemic episode or recurrent hypocalcemia with subsequent doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26093811']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26093811'])">Ref</a></span>). Resolution (with calcium supplementation) usually occurs within ~30 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26093811','lexi-content-ref-27980413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26093811','lexi-content-ref-27980413'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; related to the pharmacologic action. Denosumab inhibits osteoclastic bone resorption which causes an imbalance of osteoclast and osteoblastic activity reducing the amount of skeletal calcium released into circulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18057140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18057140'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; Usually occurs ~1 to 2 weeks after treatment initiation; however, a delayed onset (several months after treatment initiation) has also occurred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26093811','lexi-content-ref-30144112','lexi-content-ref-27980413','lexi-content-ref-28382583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26093811','lexi-content-ref-30144112','lexi-content-ref-27980413','lexi-content-ref-28382583'])">Ref</a></span>). Hypocalcemia may appear after the first dose of denosumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28382583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28382583'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting hypocalcemia</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney dysfunction; risk increases with degree of impairment (especially patients with CrCl &lt;30 mL/minute and/or on dialysis with inadequate/no calcium supplementation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30187112','lexi-content-ref-29713798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30187112','lexi-content-ref-29713798'])">Ref</a></span>). These patients may also develop marked elevations of serum parathyroid hormone. Concomitant use of calcimimetic medications may worsen hypocalcemia.</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients predisposed to hypocalcemia or disturbances of mineral metabolism (eg, hypoparathyroidism, thyroid surgery, parathyroid surgery, malabsorption syndromes, excision of small intestine)</p>
<p style="text-indent:-2em;margin-left:6em;">• Bone metastases (especially in patients with prostate cancer or small-cell lung cancer as the primary tumor type); risk increases with the number of bone metastases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26093811','lexi-content-ref-30236112','lexi-content-ref-32017154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26093811','lexi-content-ref-30236112','lexi-content-ref-32017154'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Osteoblastic bone metastases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30236112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30236112'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other calcium-lowering agents</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with high bone turnover (eg, elevated serum alkaline phosphatase, total N-terminal propeptide of type 1 procollagen [P1NP], tartrate-resistant acid phosphatase 5b [TRACP-5b], urinary cross-linked N-telopeptide of type 1 collagen [NTX]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30144112','lexi-content-ref-27980413','lexi-content-ref-30187112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30144112','lexi-content-ref-27980413','lexi-content-ref-30187112'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (may be related to higher risk of hypocalcemia in patients with prostate cancer) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26093811','lexi-content-ref-27255807']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26093811','lexi-content-ref-27255807'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• No prior zoledronic acid administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23934346']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23934346'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">An increased incidence of infection (including <b>serious infection</b>) has been demonstrated with denosumab, mainly secondary to an increased risk of ear, nose, and throat infections (eg, pharyngitis,<b> nasopharyngitis</b>, sinusitis, otitis media, labyrinthitis) and GI infections (eg, gastroenteritis, diverticulitis, <i>H. pylori </i>gastritis, cholecystitis, appendicitis, <i>C. difficile</i>-associated disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31899506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31899506'])">Ref</a></span>). Cases of kidney and <b>urinary tract infection</b>, serious skin infections, and <b>endocarditis</b> have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27798510','lexi-content-ref-21892677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27798510','lexi-content-ref-21892677'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non-dose-related; idiosyncratic; exact mechanism unknown. Denosumab inhibits RANKL which can be found on cells of the immune system including activated T lymphocytes, B cells, dendritic cells, and monocyte-macrophages; therefore, RANKL inhibition may alter immune function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20571772']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20571772'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Not well defined. In a meta-analysis of randomized controlled trials, a higher incidence of infection was evident in treatment duration of ≥12 months but not in shorter exposures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31899506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31899506'])">Ref</a></span>). In contrast, an analysis of data from the FREEDOM trial did not find a change in the rate of infection with increasing duration of denosumab treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21892677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21892677'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Impaired immune system</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of immunosuppressive therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31899506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31899506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Venous ulcers (risk factor for skin infection) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21892677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21892677'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Skin wounds (risk factor for skin infection) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21892677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21892677'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Osteonecrosis of the jaw</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteonecrosis of the jaw</b> (ONJ), also referred to as medication-related osteonecrosis of the jaw (MRONJ), has been reported in patients receiving denosumab and is characterized by nonhealing exposed or necrotic bone in the maxillofacial region (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25234529','lexi-content-ref-25414052','lexi-content-ref-31329513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25234529','lexi-content-ref-25414052','lexi-content-ref-31329513'])">Ref</a></span>). ONJ may manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth/periodontal infection, toothache, or gingival ulceration/erosion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25234529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25234529'])">Ref</a></span>). Risk of ONJ is increased with intravenous antiresorptive therapy (ie, denosumab) as compared to the risk associated with oral bisphosphonate use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25234529','lexi-content-ref-25639776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25234529','lexi-content-ref-25639776'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose- and time-related; exact mechanism unknown. Leading hypotheses include oversuppression of bone turnover or remodeling, inhibition of blood supply, constant microtrauma, and infection/inflammation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25234529','lexi-content-ref-25414052']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25234529','lexi-content-ref-25414052'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Delayed; in one combined analysis of patients with metastatic bone disease receiving antiresorptive therapies reported that ONJ occurred from 4 to 30 months after treatment initiation (median: 14 months). Resolution occurred in 40.4% of patients and median time to resolution was ~8 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21986094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21986094'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Invasive dental procedures (eg, tooth extraction, dental implants, oral surgery) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25639776','lexi-content-ref-21986094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25639776','lexi-content-ref-21986094'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Local infection with delayed healing</p>
<p style="text-indent:-2em;margin-left:6em;">• Cancer diagnosis (as compared to patients receiving antiresorptive therapy for osteoporosis, regardless of medication used or dosing schedule) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25414052','lexi-content-ref-21986094','lexi-content-ref-26335402']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25414052','lexi-content-ref-21986094','lexi-content-ref-26335402'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">In studies of patients with cancer, a longer duration of denosumab exposure was associated with a higher incidence of ONJ, although a majority of patients had predisposing factors, including a history of poor oral hygiene, tooth extraction, or the use of a dental appliance.</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy (risk may plateau at 2 to 3 years of treatment with denosumab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21343556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21343556'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (eg, doses used in cancer settings) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30870701']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30870701'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of certain medications (eg, immunosuppressive therapy, angiogenesis inhibitor therapy, chemotherapy, systemic corticosteroids, hormone therapy, erythropoietin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25639776','lexi-content-ref-25414052','lexi-content-ref-31329513','lexi-content-ref-32408510','lexi-content-ref-28963584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25639776','lexi-content-ref-25414052','lexi-content-ref-31329513','lexi-content-ref-32408510','lexi-content-ref-28963584'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Poor oral hygiene (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25639776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25639776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use of a dental appliance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25639776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25639776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Ill-fitting dentures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25414052']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25414052'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Periodontal and/or other preexisting dental disease</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25414052','lexi-content-ref-25477311']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25414052','lexi-content-ref-25477311'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Anemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25414052']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25414052'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Coagulopathy</p>
<p style="text-indent:-2em;margin-left:6em;">• Tobacco use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31329513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31329513'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hyperthyroidism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25414052']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25414052'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25414052']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25414052'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25414052']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25414052'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F10267893"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidences with Prolia (60 mg every 6 months) or Xgeva (120 mg every 4 weeks).</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (Prolia: 5%; Xgeva: 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis (Prolia: ≤11%), eczema (Prolia: ≤11%), skin rash (≤14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypocalcemia (Prolia: 2%, including severe hypocalcemia; Xgeva: 18%, severe hypocalcemia: 3%<span class="lexi-table-link-container"> (<a aria-label="Severe Hypocalcemia table link" class="lexi-table-link" data-table-id="lexi-content-severe-hypocalcemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-severe-hypocalcemia')">table 1</a>)</span><span class="table-link" style="display:none;">Severe Hypocalcemia</span>; postmarketing literature suggests a higher incidence of ~40% [Manzaneque 2017])<span class="lexi-table-link-container"> (<a aria-label="Hypocalcemia table link" class="lexi-table-link" data-table-id="lexi-content-hypocalcemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypocalcemia')">table 2</a>)</span><span class="table-link" style="display:none;">Hypocalcemia</span>, hypophosphatemia (Xgeva: 32%; severe: 15% to 21%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Severe Hypocalcemia" frame="border" id="lexi-content-severe-hypocalcemia" rules="all">
<caption style="text-align:center;">
<b>Denosumab: Adverse Reaction: Severe Hypocalcemia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Zoledronic acid)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose (Zoledronic acid)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Zoledronic acid)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comment</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">120 mg every 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 mg/4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bone metastasis from solid tumors</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,841</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,836</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Severe hypocalcemia was defined as corrected serum calcium &lt;7 mg/dL</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypocalcemia" frame="border" id="lexi-content-hypocalcemia" rules="all">
<caption style="text-align:center;">
<b>Denosumab: Adverse Reaction: Hypocalcemia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Zoledronic acid)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose (Zoledronic acid)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo or comparator)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Female</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 mg every 6 months</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Postmenopausal women with osteoporosis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 mg every 6 months</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bone loss in patients receiving androgen deprivation therapy for prostate cancer or adjuvant aromatase inhibitor therapy for breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">731</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">725</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">120 mg every 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 mg/4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bone metastasis from solid tumors</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,841</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,836</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (Xgeva: 20% to 34%), nausea (Xgeva: 31% to 32%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (Xgeva: 22%), thrombocytopenia (Xgeva: 19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (Xgeva: ≤45%), headache (Prolia: 4%; Xgeva: 11% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (Prolia: 7% to 14%), asthenia (Xgeva: ≤45%), back pain (Prolia: 5% to 12%; Xgeva: 21%), limb pain (Prolia: 10% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (Xgeva: 15%), dyspnea (Xgeva: 21%), upper respiratory tract infection (Prolia: 3% to 5%; Xgeva: 15%)<span class="lexi-table-link-container"> (<a aria-label="Upper Respiratory Tract Infection table link" class="lexi-table-link" data-table-id="lexi-content-upper-respiratory-tract-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-upper-respiratory-tract-infection')">table 3</a>)</span><span class="table-link" style="display:none;">Upper Respiratory Tract Infection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Upper Respiratory Tract Infection" frame="border" id="lexi-content-upper-respiratory-tract-infection" rules="all">
<caption style="text-align:center;">
<b>Denosumab: Adverse Reaction: Upper Respiratory Tract Infection</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Bisphosphonate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose (Bisphosphonate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo or comparator)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Female</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 mg every 6 months</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Postmenopausal women with osteoporosis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,886</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,876</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 mg every 6 months</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Glucocorticoid-induced osteoporosis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">394</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">384</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris (Prolia: 3%), hypertension (Prolia: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercholesterolemia (Prolia: 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (Prolia: 3%), dyspepsia (Prolia: 3%), flatulence (Prolia: 2%), upper abdominal pain (Prolia: 3%), vomiting (Prolia 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (Prolia: 3%)<span class="lexi-table-link-container"> (<a aria-label="Urinary Tract Infection table link" class="lexi-table-link" data-table-id="lexi-content-urinary-tract-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-urinary-tract-infection')">table 4</a>)</span><span class="table-link" style="display:none;">Urinary Tract Infection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Urinary Tract Infection" frame="border" id="lexi-content-urinary-tract-infection" rules="all">
<caption style="text-align:center;">
<b>Denosumab: Adverse Reaction: Urinary Tract Infection</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Bisphosphonate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose (Bisphosphonate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Bisphosphonate)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 mg every 6 months</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Glucocorticoid-induced osteoporosis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">394</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">384</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Malignant neoplasm (Prolia: new; 3% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Serious infection (Prolia: 4%)<span class="lexi-table-link-container"> (<a aria-label="Serious Infection table link" class="lexi-table-link" data-table-id="lexi-content-serious-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-serious-infection')">table 5</a>)</span><span class="table-link" style="display:none;">Serious Infection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Serious Infection" frame="border" id="lexi-content-serious-infection" rules="all">
<caption style="text-align:center;">
<b>Denosumab: Adverse Reaction: Serious Infection</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Bisphosphonate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose (Bisphosphonate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Bisphosphonate)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 mg every 6 months</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Glucocorticoid-induced osteoporosis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">394</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">384</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (Prolia: 2%), falling (Prolia: 2%), sciatica (Prolia: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain (Prolia: 6%), myalgia (Prolia: 3%), ostealgia (Prolia: 4%), osteonecrosis of the jaw (Prolia: &lt;1%; Xgeva: 2%)<span class="lexi-table-link-container"> (<a aria-label="Osteonecrosis of the Jaw table link" class="lexi-table-link" data-table-id="lexi-content-osteonecrosis-of-the-jaw" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-osteonecrosis-of-the-jaw')">table 6</a>)</span><span class="table-link" style="display:none;">Osteonecrosis of the Jaw</span>, polymyalgia rheumatica (Prolia: 2%), vertebral column fracture (following discontinuation: Prolia: 3% to 6%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Osteonecrosis of the Jaw" frame="border" id="lexi-content-osteonecrosis-of-the-jaw" rules="all">
<caption style="text-align:center;">
<b>Denosumab: Adverse Reaction: Osteonecrosis of the Jaw</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Zoledronic acid)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose (Zoledronic acid)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Zoledronic acid)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">120 mg every 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 mg/4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bone metastasis from solid tumors</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,841</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,836</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Cataract (Prolia: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (Prolia: 4%)<span class="lexi-table-link-container"> (<a aria-label="Bronchitis table link" class="lexi-table-link" data-table-id="lexi-content-bronchitis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-bronchitis')">table 7</a>)</span><span class="table-link" style="display:none;">Bronchitis</span>, nasopharyngitis (Prolia: 7%)<span class="lexi-table-link-container"> (<a aria-label="Nasopharyngitis table link" class="lexi-table-link" data-table-id="lexi-content-nasopharyngitis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nasopharyngitis')">table 8</a>)</span><span class="table-link" style="display:none;">Nasopharyngitis</span>, pneumonia (Xgeva: 8%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Bronchitis" frame="border" id="lexi-content-bronchitis" rules="all">
<caption style="text-align:center;">
<b>Denosumab: Adverse Reaction: Bronchitis</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Bisphosphonate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose (Bisphosphonate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Bisphosphonate)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 mg every 6 months</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Glucocorticoid-induced osteoporosis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">394</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">384</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Nasopharyngitis" frame="border" id="lexi-content-nasopharyngitis" rules="all">
<caption style="text-align:center;">
<b>Denosumab: Adverse Reaction: Nasopharyngitis</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Male</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Osteoporosis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">120</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">120</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Endocarditis (Prolia)<span class="lexi-table-link-container"> (<a aria-label="Endocarditis table link" class="lexi-table-link" data-table-id="lexi-content-endocarditis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-endocarditis')">table 9</a>)</span><span class="table-link" style="display:none;">Endocarditis</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Endocarditis" frame="border" id="lexi-content-endocarditis" rules="all">
<caption style="text-align:center;">
<b>Denosumab: Adverse Reaction: Endocarditis</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Denosumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Female</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Postmenopausal women with osteoporosis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,886</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,876</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (all formulations):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Vasculitis (Sanchez 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (Lyakhovitsky 2016), erythema of skin, facial swelling (Gutiérrez-Fernández 2015), lichenoid eruption (King 2018), urticaria (Gutiérrez-Fernández 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; Metabolic: Hyperparathyroidism (Mazokopakis 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (Malnick 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Al-Attar 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Femur fracture (atypical, diaphyseal, subtrochanteric) (Selga 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Epithelial keratopathy (Nguyen 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute interstitial nephritis (Philipponnet 2018)</p></div>
<div class="block coi drugH1Div" id="F10267537"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Prolia: Hypersensitivity (systemic) to denosumab or any component of the formulation; preexisting hypocalcemia; pregnancy</p>
<p style="text-indent:-2em;margin-left:2em;">Xgeva: Known clinically significant hypersensitivity to denosumab or any component of the formulation; preexisting hypocalcemia</p></div>
<div class="block war drugH1Div" id="F10267891"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone fractures: Atypical femur fractures have been reported in patients receiving denosumab. The fractures may occur anywhere along the femoral shaft (may be bilateral) and commonly occur with minimal to no trauma to the area. Some patients experience prodromal pain weeks or months before the fracture occurs. Because these fractures also occur in osteoporosis patients not treated with denosumab, it is unclear if denosumab therapy is the cause for the fractures; concomitant glucocorticoids may contribute to fracture risk. Advise patients to report new/unusual hip, thigh, or groin pain; and if so, evaluate for atypical/incomplete fracture. Contralateral limb should be assessed if atypical fracture occurs. Consider interrupting therapy in patients who develop an atypical femoral fracture. Following treatment discontinuation, the fracture risk increases, including risk of multiple vertebral fractures; patients with a history of prior fractures or osteoporosis are at higher risk. Vertebral fractures occurred as early as 7 months (average: 19 months) after the last dose of denosumab. Evaluate benefit/risk before initiating denosumab treatment for osteoporosis, especially in patients with prior vertebral fracture. If denosumab is discontinued, evaluate risk for vertebral fracture and consider transitioning to an alternative osteoporosis therapy. Because denosumab is associated with a severe bone turnover rebound following discontinuation, post-denosumab antiresorptive therapy (eg, bisphosphonate therapy or alternative) is suggested to mitigate decline in bone mineral density (ES [Eastell 2019]; Tsourdi 2017). Bisphosphonate therapy following denosumab discontinuation may reduce/prevent bone turnover rebound (Lamy 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic reactions: Dermatitis, eczema, and rash (which are not necessarily specific to the injection site) have been reported. Consider discontinuing if severe symptoms occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Clinically significant hypersensitivity (including anaphylaxis) has been reported. May include throat tightness, facial edema, upper airway edema, lip swelling, dyspnea, pruritus, rash, urticaria, and hypotension. If anaphylaxis or clinically significant hypersensitivity occurs, initiate appropriate management and permanently discontinue.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypercalcemia: Hypercalcemia (clinically significant requiring hospitalization and complicated by acute renal injury) may occur in patients with giant cell tumor of bone and patients with growing skeletons weeks to months following discontinuation of denosumab therapy. Monitor for signs/symptoms of hypercalcemia (eg, nausea, vomiting, headache, decreased alertness), assess serum calcium periodically, and treat accordingly.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypocalcemia: Denosumab may cause or exacerbate hypocalcemia; severe symptomatic cases (including fatalities) have been reported. An increased risk has been observed with increasing renal dysfunction, most commonly severe dysfunction (CrCl &lt;30 mL/minute and/or on dialysis), and with inadequate/no calcium supplementation. Monitor calcium levels; correct preexisting hypocalcemia prior to therapy. Monitor levels more frequently when denosumab is administered with other drugs that can also lower calcium levels. Use caution in patients with a history of hypoparathyroidism, thyroid surgery, parathyroid surgery, malabsorption syndromes, excision of small intestine, severe renal impairment/dialysis, treatment with other calcium-lowering agents, or other conditions that would predispose the patient to hypocalcemia; monitor calcium, phosphorus, and magnesium closely during therapy (the manufacturer recommends monitoring within 14 days of injection [Prolia] or during the first weeks of therapy initiation [Xgeva]). Concomitant use of calcimimetic medications may worsen hypocalcemia. Hypocalcemia lasting weeks to months (and requiring frequent monitoring) has been reported in postmarketing analyses. Administer calcium, vitamin D, and magnesium as necessary. Patients with severe renal impairment (CrCl &lt;30 mL/minute) or those on dialysis may also develop marked elevations of serum parathyroid hormone (PTH).</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Incidence of infections may be increased, including serious skin infections, abdominal, urinary, ear, or periodontal infections. Endocarditis has also been reported following use. Patients should be advised to contact their healthcare provider if signs or symptoms of severe infection or cellulitis develop. Use with caution in patients with impaired immune systems or using concomitant immunosuppressive therapy; may be at increased risk for serious infections. Evaluate the need for continued treatment with serious infection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Osteonecrosis of the jaw: Osteonecrosis of the jaw (ONJ), also referred to as medication-related osteonecrosis of the jaw (MRONJ), has been reported in patients receiving denosumab. ONJ may manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth/periodontal infection, toothache, gingival ulceration/erosion. Risk factors include invasive dental procedures (eg, tooth extraction, dental implants, oral surgery), cancer diagnosis, immunosuppressive therapy, angiogenesis inhibitor therapy, chemotherapy, systemic corticosteroids, poor oral hygiene, use of a dental appliance, ill-fitting dentures, periodontal and/or other preexisting dental disease, diabetes and gingival infections, local infection with delayed healing, anemia, and/or coagulopathy. In studies of patients with cancer, a longer duration of denosumab exposure was associated with a higher incidence of ONJ, although a majority of patients had predisposing factors, including a history of poor oral hygiene, tooth extraction, or the use of a dental appliance. Patients should maintain good oral hygiene during treatment. A dental exam and appropriate preventive dentistry should be performed prior to therapy. The manufacturer's labeling recommends avoiding invasive dental procedures in patients with bone metastases receiving denosumab for prevention of skeletal-related events and to consider temporary discontinuation of therapy in these patients if invasive dental procedure is required. According to a position paper by the American Association of Maxillofacial Surgeons (AAOMS), MRONJ has been associated with bisphosphonates and other antiresorptive agents (denosumab), and antiangiogenic agents (eg, bevacizumab, sunitinib) used for the treatment of osteoporosis or malignancy; risk is significantly higher in cancer patients receiving antiresorptive therapy compared to patients receiving osteoporosis treatment (regardless of medication used or dosing schedule). MRONJ risk is increased with intravenous antiresorptive therapy compared to the minimal risk associated with oral bisphosphonate use, although risk appears to increase with oral bisphosphonates when duration of therapy exceeds 4 years. The AAOMS suggests that if medically permissible, initiation of denosumab for cancer therapy should be delayed until optimal dental health is attained (if extractions are required, antiresorptive therapy should delayed until the extraction site has mucosalized or until after adequate osseous healing). Once denosumab is initiated for oncologic disease, procedures that involve direct osseous injury and placement of dental implants should be avoided. Patients developing ONJ during therapy should receive care by an oral surgeon (AAOMS [Ruggiero 2014]). According to the manufacturer, discontinuation of denosumab should be considered (based on risk/benefit evaluation) in patients who develop ONJ.</p>
<p style="text-indent:-2em;margin-left:4em;">• Musculoskeletal pain: Severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported (time to onset of symptoms has varied from one day to several months after initiating therapy). Consider discontinuing use if severe symptoms develop.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Breast cancer: The American Society of Clinical Oncology (ASCO)/Cancer Care Ontario (CCO) updated guidelines on the role of bone-modifying agents (BMAs) in metastatic breast cancer patients (ASCO/CCO [Van Poznak 2017]). The guidelines recommend initiating a BMA (denosumab, pamidronate, zoledronic acid) in patients with metastatic breast cancer to the bone. One BMA is not recommended over another (evidence supporting one BMA over another is insufficient). The optimal duration of BMA therapy is not defined; however, the guidelines recommend continuing BMA therapy indefinitely. The analgesic effect of BMAs are modest and BMAs should not be used alone for pain management; supportive care, analgesics, adjunctive therapies, radiation therapy, surgery, and/or systemic anticancer therapy should be utilized.</p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple myeloma: The American Society of Clinical Oncology (ASCO) has updated guidelines on the role of BMAs in multiple myeloma (ASCO [Anderson 2018]). The update now includes denosumab as an alternate to zoledronic acid or pamidronate in patients with lytic disease, and as an additional option in adjunctive pain control in patients with pain due to osteolytic disease and patients receiving other interventions for fractures or impending fractures. Denosumab may also be preferred (to zoledronic acid) in patients with renal impairment. The ASCO guidelines recommend continuing the BMA for up to 2 years in multiple myeloma patients; BMAs may then be resumed upon relapse with new onset skeletal-related events. Denosumab has a reversible mechanism of action and therefore should not be discontinued abruptly (refer to Bone fractures [above] for further information).</p>
<p style="text-indent:-2em;margin-left:4em;">• Osteoporosis in survivors of adult cancers (nonmetastatic disease): Survivors of adult cancers with nonmetastatic disease who have osteoporosis (T score of -2.5 or lower in femoral neck, total hip, or lumbar spine) or who are at increased risk of osteoporotic fractures, should be offered bone modifying agents (utilizing the osteoporosis-indicated dose) to reduce the risk of fracture. For patients without hormonal responsive cancers, when clinically appropriate, estrogens may be administered along with other bone modifying agents (ASCO [Shapiro 2019]). The choice of bone modifying agent (eg, oral or IV bisphosphonates or subQ denosumab) should be based on several factors (eg, patient preference, potential adverse effects, quality of life considerations, availability, adherence, cost). Adequate calcium and vitamin D intake, exercise (using a combination of exercise types), as well as lifestyle modifications (if indicated), should also be encouraged.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment (CrCl &lt;30 mL/minute) or patients on dialysis; risk of hypocalcemia is increased. Dose adjustment is not needed when administered at 60 mg every 6 months (Prolia); once-monthly dosing has not been evaluated in patients with renal impairment (Xgeva).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: Packaging may contain natural latex rubber (<b>Note:</b> Prior to January 2023, the Prolia prescribing information stated the prefilled syringe gray needle cap contained dry natural rubber).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: May impair bone growth in children with open growth plates or inhibit eruption of dentition. Indicated only for the treatment of giant cell tumor of bone in adolescents who are skeletally mature.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Postmenopausal osteoporosis: For use in females at high risk for fracture which is defined as a history of osteoporotic fracture or multiple risk factors for fracture. May also be used in females who failed or did not tolerate other therapies.</p>
<p style="text-indent:-2em;margin-left:4em;">• Duplicate therapy: Do not administer Prolia and Xgeva to the same patient for different indications.</p>
<p style="text-indent:-2em;margin-left:4em;">• Long-term therapy: Denosumab therapy results in significant suppression of bone turnover; the long-term effects of treatment are not known, but may contribute to adverse outcomes such as ONJ, atypical fractures, or delayed fracture healing; monitor.</p></div>
<div class="block dosfc drugH1Div" id="F53766120"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Prolia prefilled syringe gray needle cap contains dry natural rubber (a derivative of latex).</p></div>
<div class="block foc drugH1Div" id="F10267951"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xgeva: 120 mg/1.7 mL (1.7 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Prolia: 60 mg/mL (1 mL)</p></div>
<div class="block geq drugH1Div" id="F10267527"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322854"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Xgeva Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg/1.7 mL (per mL): $2,254.89</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Prolia Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg/mL (per mL): $2,083.96</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871175"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xgeva: 120 mg/1.7 mL (1.7 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Prolia: 60 mg/mL (1 mL) [contains mouse (murine) and/or hamster protein]</p></div>
<div class="block adm drugH1Div" id="F10267946"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>SUBQ:</b> Denosumab is intended for SUBQ route only and should not be administered IV, IM, or intradermally. Prior to administration, bring to room temperature in original container (allow to stand ~15 to 30 minutes); do not warm by any other method. Solution may contain trace amounts of translucent to white protein particles; do not use if cloudy, discolored (normal solution should be clear and colorless to pale yellow), or contains excessive particles or foreign matter. Avoid vigorous shaking. Administer via SUBQ injection in the upper arm, upper thigh, or abdomen; should only be administered by a health care professional.</p></div>
<div class="block admp drugH1Div" id="F52614455"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">SubQ: Administer by SubQ injection only; do not administer intravenously, intramuscularly, or intradermally. Prior to administration, bring to room temperature in original container (allow to stand ~15 to 30 minutes); do not warm by any other method. Solution may contain trace amounts of translucent to white protein particles; do not use if cloudy, discolored (normal solution should be clear and colorless to pale yellow), or contains excessive particles or foreign matter. Avoid vigorous shaking. Administer via SubQ injection in the upper arm, upper thigh, or abdomen; should only be administered by a health care professional.</p>
<p style="text-indent:-2em;margin-left:2em;">Xgeva: Use 27 gauge needle to withdraw dose from vial and administer subcutaneously.</p></div>
<div class="block meg drugH1Div" id="F10267524"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Prolia: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F125320s210lbl.pdf%23page%3D31&amp;token=4peAQseKcn64mo9hE2huGe7TK%2BLI9c8MTENxuBd8HN5R5fVFgXj%2FlFug3W9kATNFNFfQe%2F4ObWb15dmA5Cj4j0qtUkD6C7nQJ3cQ7uCDWQsLIQTxpH%2F5X3%2BSBBFZ9TXZ&amp;TOPIC_ID=15575" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125320s210lbl.pdf#page=31</a></p></div>
<div class="block use drugH1Div" id="F10267530"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Bone metastases from solid tumors (Xgeva):</b> Prevention of skeletal-related events in patients with bone metastases from solid tumors.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Giant cell tumor of bone (Xgeva):</b> Treatment of giant cell tumor of bone (in adults and skeletally mature adolescents) that is unresectable or where surgical resection is likely to result in severe morbidity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypercalcemia of malignancy (Xgeva):</b> Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma (Xgeva):</b> Prevention of skeletal-related events in patients with multiple myeloma.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis/bone loss (Prolia):</b> Treatment of osteoporosis in postmenopausal females at high risk of fracture; treatment of osteoporosis (to increase bone mass) in males at high risk of fracture; treatment of bone loss (to increase bone mass) in males receiving androgen-deprivation therapy for nonmetastatic prostate cancer; treatment of bone loss (to increase bone mass) in females receiving aromatase inhibitor therapy for breast cancer; treatment of glucocorticoid-induced osteoporosis in patients at high risk of fracture who are initiating or continuing systemic glucocorticoids at a daily dose equivalent to ≥7.5 mg of prednisone for an anticipated duration of at least 6 months (high risk defined as osteoporotic fracture history, multiple risk factors for fracture, or failure of or intolerance to other available osteoporosis therapy).</p></div>
<div class="block off-label drugH1Div" id="F25475121"><span class="drugH1">Use: Off-Label: Adult</span><p>Bone destruction caused by rheumatoid arthritis</p></div>
<div class="block mst drugH1Div" id="F13254398"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Denosumab may be confused with daclizumab, daratumumab, dinutuximab, dupilumab, durvalumab</p>
<p style="text-indent:-2em;margin-left:4em;">Prolia may be confused with Udenyca</p>
<p style="text-indent:-2em;margin-left:4em;">Xgeva may be confused with Jevtana, Xofigo, Xtandi, Zometa, Zytiga</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Duplicate therapy issues: Prolia contains denosumab, which is the same ingredient contained in Xgeva; patients receiving Xgeva should not be treated with Prolia</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299134"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F10327798"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Calcimimetic Agents: Denosumab may enhance the hypocalcemic effect of Calcimimetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): Denosumab may enhance the immunosuppressive effect of Corticosteroids (Systemic).  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and systemic corticosteroids. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): Denosumab may enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): Denosumab may enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May enhance the immunosuppressive effect of Denosumab. Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Denosumab may enhance the immunosuppressive effect of Methotrexate.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants, such as methotrexate. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49297811"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in females of reproductive potential. Females of reproductive potential should be advised to use effective contraception during denosumab treatment and for at least 5 months following the last denosumab dose. Studies of denosumab following a single 60 mcg subcutaneous dose in healthy men demonstrated that denosumab is present in the semen in low concentrations (~2% of serum exposure) and therefore unlikely that a female partner or fetus would be exposed during unprotected sex to pharmacologically relevant denosumab concentrations via seminal fluid (Sohn 2016).</p></div>
<div class="block pri drugH1Div" id="F10267533"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to denosumab may cause fetal harm. Denosumab is a humanized monoclonal antibody (IgG<sub>2</sub>). Potential placental transfer of human IgG is dependent upon the IgG subclass and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009). Use of Prolia is contraindicated during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to denosumab is ongoing. Health care providers are encouraged to enroll females exposed to denosumab during pregnancy in the Amgen Pregnancy Surveillance Program (1-800-772-6436).</p></div>
<div class="block brc drugH1Div" id="F10267536"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if denosumab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F10267899"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Ensure adequate calcium and vitamin D intake to prevent or treat hypocalcemia. Calcium 1,000 mg/day and vitamin D ≥400 units/day is recommended in product labeling (Prolia). If dietary intake is inadequate, dietary supplementation is recommended. Patients should consume:</p>
<p style="text-indent:-2em;margin-left:2em;">Calcium: 1,000 mg/day (males: 50 to 70 years of age) <b>or</b> 1,200 mg/day (females ≥51 years of age and males ≥71 years of age) (IOM 2011; NOF 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D: 800 to 1,000 units/day (age ≥50 years) (NOF 2014). Recommended dietary allowance (RDA): 600 units/day (age ≤70 years) <b>or</b> 800 units/day (age ≥71 years) (IOM 2011).</p></div>
<div class="block mop drugH1Div" id="F10267948"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Serum creatinine, serum calcium, phosphorus and magnesium (especially within the first 14 days of therapy [Prolia] or during the first weeks of therapy initiation [Xgeva]), pregnancy test (prior to treatment initiation in females of reproductive potential); signs/symptoms of hypocalcemia, especially in patients predisposed to hypocalcemia (severe renal impairment, thyroid/parathyroid surgery, malabsorption syndromes, hypoparathyroidism); signs/symptoms of hypercalcemia, including periodic serum calcium (following discontinuation in patients with giant cell tumor of the bone and patients with growing skeletons); infection, or dermatologic reactions; routine oral exam (prior to treatment); dental exam if risk factors for ONJ; signs/symptoms of hypersensitivity.</p>
<p style="text-indent:-2em;margin-left:2em;">Osteoporosis: Serial bone mineral density (BMD) should be evaluated at baseline and every 1 to 3 years (usually at ~2 years following initiation of therapy, then more or less frequently depending on patient-specific factors and stability of BMD) (AACE/ACE [Camacho 2020]; ES [Eastell 2019]; NOF [Cosman 2014]); may consider monitoring biochemical markers of bone turnover (eg, fasting serum CTX or urinary NTX) at baseline, 3 months, and 6 months, to assess treatment response (ES [Eastell 2019]).</p>
<p style="text-indent:-2em;margin-left:2em;">Patients with cancer: The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F10267944"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Denosumab is a monoclonal antibody with affinity for nuclear factor-kappa ligand (RANKL). Osteoblasts secrete RANKL; RANKL activates osteoclast precursors and subsequent osteolysis which promotes release of bone-derived growth factors, such as insulin-like growth factor-1 (IGF1) and transforming growth factor-beta (TGF-beta), and increases serum calcium levels. Denosumab binds to RANKL, blocks the interaction between RANKL and RANK (a receptor located on osteoclast surfaces), and prevents osteoclast formation, leading to decreased bone resorption and increased bone mass in osteoporosis. In solid tumors with bony metastases, RANKL inhibition decreases osteoclastic activity leading to decreased skeletal related events and tumor-induced bone destruction. In giant cell tumors of the bone (which express RANK and RANKL), denosumab inhibits tumor growth by preventing RANKL from activating its receptor (RANK) on the osteoclast surface, osteoclast precursors, and osteoclast-like giant cells.</p></div>
<div class="block phk drugH1Div" id="F10267902"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Decreases markers of bone resorption by ~85% within 3 days; maximal reductions observed within 1 month.</p>
<p style="text-indent:-2em;margin-left:4em;">Hypercalcemia of malignancy: Time to response (median): 9 days; Time to complete response (median): 23 days (Hu 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Markers of bone resorption return to baseline within 12 months of discontinuing therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Hypercalcemia of malignancy: Duration of response (median): 104 days; Duration of complete response (median): 34 days (Hu 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SUBQ: 62%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~25 to 28 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 10 days (range: 3 to 21 days).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10962022"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Denosis</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Xgeva</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Prolia</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Prolia</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Xgeva</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Debrumab | Denaxa | Denbri | Deninta | Denoci | Denoclast | Denosurel | Densurank | Denu | Denub | Denuril | Esentra | Nuclasta | Ogain | Olimab | Prolia | Rozel | Xgeva</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Pralia | Ranmark</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Prolia</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Prolia</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Prolia</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Xgeva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Xgeva</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Prolia | Xgeva</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-23097066">
<a name="23097066"></a>Adami S, Libanati C, Boonen S, et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. <i>J Bone Joint Surg Am</i>. 2012;94(23):2113-2119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/23097066/pubmed" id="23097066" target="_blank">23097066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29339529">
<a name="29339529"></a>Adler RA. Management of endocrine disease: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy. <i>Eur J Endocrinol</i>. 2018;178(3):R81-R87. doi:10.1530/EJE-17-1002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/29339529/pubmed" id="29339529" target="_blank">29339529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31890758">
<a name="31890758"></a>Al-Attar M, De Santis M, Massarotti M. DRESS syndrome in response to Denosumab: First documented case report. <i>Bone Rep</i>. 2019;12:100239. doi:10.1016/j.bonr.2019.100239<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/31890758/pubmed" id="31890758" target="_blank">31890758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32373677">
<a name="32373677"></a>Anastasilakis AD, Evangelatos G, Makras P, Iliopoulos A. Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation. <i>Bone Rep</i>. 2020;12:100267. doi:10.1016/j.bonr.2020.100267<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/32373677/pubmed" id="32373677" target="_blank">32373677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29341831">
<a name="29341831"></a>Anderson K, Ismaila N, Flynn PJ, et al. Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update [published online ahead of print January 17, 2018]. <i>J Clin Oncol</i>. 2018:JCO2017766402. doi: 10.1200/JCO.2017.76.6402.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/29341831/pubmed" id="29341831" target="_blank">29341831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bailie.2020">
<a name="Bailie.2020"></a>Bailie G, Mason M. 2020 Dialysis of Drugs. Renal Pharmacy Consultants, LLC; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34515963">
<a name="34515963"></a>Barth K, Sedivy M, Lindner G, Schwarz C. Successful treatment with denosumab for two cases with hypercalcemia due to vitamin D intoxication and associated acute kidney injury. <i>CEN Case Rep</i>. 2022;11(1):141-145. doi:10.1007/s13730-021-00643-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/34515963/pubmed" id="34515963" target="_blank">34515963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.1">
<a name="Expert.1"></a>Based on expert opinion.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22711097">
<a name="22711097"></a>Bech A, de Boer H. Denosumab for tumor-induced hypercalcemia complicated by renal failure. <i>Ann Intern Med</i>. 2012;156(12):906-907. doi:10.7326/0003-4819-156-12-201206190-00026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/22711097/pubmed" id="22711097" target="_blank">22711097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31016056">
<a name="31016056"></a>Bhanot RD, Kaur J, Bhat Z. Severe hypocalcemia and dramatic increase in parathyroid hormone after denosumab in a dialysis patient: a case report and review of the literature. <i>Case Rep Nephrol.</i> 2019. doi:10.1155/2019/3027419<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/31016056/pubmed" id="31016056" target="_blank">31016056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Blay.2011">
<a name="Blay.2011"></a>Blay J, Chawla SP, Martin Broto J, et al. Denosumab safety and efficacy in giant cell tumor of bone (GCTB): Interim results from A phase II study. <i>J Clin Oncol.</i> 2011;29(18s):10034 [abstract 10034 from 2011 ASCO Annual Meeting].</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22461041">
<a name="22461041"></a>Block GA, Bone HG, Fang L, et al. A Single-Dose Study of Denosumab in Patients With Various Degrees of Renal Impairment. <i>J Bone Miner Res.</i> 2012;27(7):1471-1479.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/22461041/pubmed" id="22461041" target="_blank">22461041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26093811">
<a name="26093811"></a>Body JJ, Bone HG, de Boer RH, et al. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. <i>Eur J Cancer</i>. 2015;51(13):1812-1821. doi:10.1016/j.ejca.2015.05.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/26093811/pubmed" id="26093811" target="_blank">26093811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19653815">
<a name="19653815"></a>Body JJ, Lipton A, Gralow J, et al. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. <i>J Bone Miner Res.</i> 2010;25(3):440-446.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/19653815/pubmed" id="19653815" target="_blank">19653815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30236112">
<a name="30236112"></a>Body JJ, von Moos R, Niepel D, Tombal B. Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion. <i>BMC Urol</i>. 2018;18(1):81. doi:10.1186/s12894-018-0393-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/30236112/pubmed" id="30236112" target="_blank">30236112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27798510">
<a name="27798510"></a>Bonani M, Frey D, de Rougemont O, et al. Infections in de novo kidney transplant recipients treated with the RANKL inhibitor denosumab. <i>Transplantation</i>. 2017;101(9):2139-2145. doi:10.1097/TP.0000000000001547<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/27798510/pubmed" id="27798510" target="_blank">27798510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21289258">
<a name="21289258"></a>Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. <i>J Clin Endocrinol Metab.</i> 2011;96(4):972-980.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/21289258/pubmed" id="21289258" target="_blank">21289258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21411557">
<a name="21411557"></a>Boonen S, Adachi JD, Man Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. <i>J Clin Endocrinol Metab.</i> 2011;96(6):1727-1736.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/21411557/pubmed" id="21411557" target="_blank">21411557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25639776">
<a name="25639776"></a>Boquete-Castro A, Gómez-Moreno G, Calvo-Guirado JL, Aguilar-Salvatierra A, Delgado-Ruiz RA. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. <i>Clin Oral Implants Res</i>. 2016;27(3):367-375. doi:10.1111/clr.12556<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/25639776/pubmed" id="25639776" target="_blank">25639776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22711702">
<a name="22711702"></a>Branstetter DG, Nelson SD, Manivel JC, et al. Denosumab Induces Tumor Reduction and Bone Formation in Patients With Giant-Cell Tumor of Bone. <i>Clin Cancer Res.</i> 2012;18(16):4415-4424.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/22711702/pubmed" id="22711702" target="_blank">22711702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18767928">
<a name="18767928"></a>Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone Turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 Trial. <i>J Bone Miner Res.</i> 2009;24(1):153-161.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/18767928/pubmed" id="18767928" target="_blank">18767928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32427503">
<a name="32427503"></a>Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis–2020 update. <i>Endocr Pract</i>. 2020;26(suppl 1):1-46. doi:10.4158/GL-2020-0524SUPPL<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/32427503/pubmed" id="32427503" target="_blank">32427503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23867211">
<a name="23867211"></a>Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. <i>Lancet Oncol</i>. 2013;14(9):901-908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/23867211/pubmed" id="23867211" target="_blank">23867211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18438830">
<a name="18438830"></a>Cohen SB, Dore RK, Lane NE, et al. Denosumab Treatment Effects on Structural Damage, Bone Mineral Density, and Bone Turnover in Rheumatoid Arthritis: A Twelve-Month, Multicenter, Randomized, Double-Blind Placebo-Controlled, Phase II Clinical Trial. <i>Arthritis Rheum. </i>2008;58(5):1299-1309.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/18438830/pubmed" id="18438830" target="_blank">18438830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25182228">
<a name="25182228"></a>Cosman F, de Beur SJ, LeBoff MS, et al; National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. <i>Osteoporos Int</i>. 2014;25(10):2359-2381. doi:10.1007/s00198-014-2794-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/25182228/pubmed" id="25182228" target="_blank">25182228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19671655">
<a name="19671655"></a>Cummings SR, San Martin J, McClung MR, et al. FREEDOM trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. <i>N Engl J Med.</i> 2009;361(8):756-765.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/19671655/pubmed" id="19671655" target="_blank">19671655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29675745">
<a name="29675745"></a>Dell R, Greene D. A proposal for an atypical femur fracture treatment and prevention clinical practice guideline. <i>Osteoporos Int</i>. 2018;29(6):1277-1283. doi:10.1007/s00198-018-4506-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/29675745/pubmed" id="29675745" target="_blank">29675745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24072245">
<a name="24072245"></a>Demirsoy U, Karadogan M, Selek Ö, et al. Golden bullet-denosumab: early rapid response of metastatic giant cell tumor of the bone. <i>J Pediatr Hematol Oncol</i>. 2014;36(2):156-158.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/24072245/pubmed" id="24072245" target="_blank">24072245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31899506">
<a name="31899506"></a>Diker-Cohen T, Rosenberg D, Avni T, Shepshelovich D, Tsvetov G, Gafter-Gvili A. Risk for infections during treatment with denosumab for osteoporosis: a systematic review and meta-analysis. <i>J Clin Endocrinol Metab</i>. 2020;105(5):dgz322. doi:10.1210/clinem/dgz322<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/31899506/pubmed" id="31899506" target="_blank">31899506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19734132">
<a name="19734132"></a>Dore RK, Cohen SB, Lane NE, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. <i>Ann Rheum Dis. </i>2010;69(5):872-875.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/19734132/pubmed" id="19734132" target="_blank">19734132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32487552">
<a name="32487552"></a>Dupont J, Laurent MR, Dedeyne L, Luyten FP, Gielen E, Dejaeger M. Vertebral fractures after denosumab cessation. <i>Cleve Clin J Med</i>. 2020;87(6):337-338. doi:10.3949/ccjm.87a.19152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/32487552/pubmed" id="32487552" target="_blank">32487552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30907953">
<a name="30907953"></a>Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1595-1622. doi:10.1210/jc.2019-00221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/30907953/pubmed" id="30907953" target="_blank">30907953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18725648">
<a name="18725648"></a>Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. <i>J Clin Oncol. </i>2008;26(30):4875-4882.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/18725648/pubmed" id="18725648" target="_blank">18725648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22901640">
<a name="22901640"></a>Epstein MS, Ephros HD, Epstein JB. Review of current literature and implications of RANKL inhibitors for oral health care providers. <i>Oral Surg Oral Med Oral Path Oral Radiol.</i> 2013;116(6):e437-e444.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/22901640/pubmed" id="22901640" target="_blank">22901640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Export.DOR">
<a name="Export.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDASafety.2016">
<a name="FDASafety.2016"></a>FDA Safety Alert. Medwatch. Summary Safety Review - Denosumab (Prolia and Xgeva) - Hearing loss and deafness<b>.</b>
<a href="http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/denosumab" target="_blank">http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/denosumab</a>. Published June 6, 2016. Accessed June 17, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32092479">
<a name="32092479"></a>Ferrari S, Lewiecki EM, Butler PW, et al. Favorable skeletal benefit/risk of long-term denosumab therapy: a virtual-twin analysis of fractures prevented relative to skeletal safety events observed. <i>Bone</i>. 2020;134:115287. doi:10.1016/j.bone.2020.115287<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/32092479/pubmed" id="32092479" target="_blank">32092479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20571772">
<a name="20571772"></a>Ferrari-Lacraz S, Ferrari S. Do RANKL inhibitors (denosumab) affect inflammation and immunity? <i>Osteoporos Int</i>. 2011;22(2):435-446. doi:10.1007/s00198-010-1326-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/20571772/pubmed" id="20571772" target="_blank">20571772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21353695">
<a name="21353695"></a>Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. <i>Lancet.</i> 2011;377(9768):813-822.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/21353695/pubmed" id="21353695" target="_blank">21353695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27896639">
<a name="27896639"></a>Grávalos C, Rodríguez C, Sabino A, et al. SEOM Clinical Guideline for bone metastases from solid tumours (2016). <i>Clin Transl Oncol</i>. 2016;18(12):1243-1253.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/27896639/pubmed" id="27896639" target="_blank">27896639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26504466">
<a name="26504466"></a>Gutiérrez-Fernández D, Cruz MJ, Foncubierta-Fernández A, et al. Monoclonal antibody desensitization in a patient with a generalized urticarial reaction following denosumab administration. <i>Allergy Asthma Clin Immunol</i>. 2015;11:29. doi:10.1186/s13223-015-0097-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/26504466/pubmed" id="26504466" target="_blank">26504466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21343556">
<a name="21343556"></a>Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab verses zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. <i>J Clin Oncol.</i> 2011;29(9):1125-1132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/21343556/pubmed" id="21343556" target="_blank">21343556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24915117">
<a name="24915117"></a>Hu MI, Glezerman IG, Leboulleux S, et al. Denosumab for treatment of hypercalcemia of malignancy. <i>J Clin Endocrinol Metab</i>. 2014;99(9):3144-3152. doi:10.1210/jc.2014-1001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/24915117/pubmed" id="24915117" target="_blank">24915117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27255807">
<a name="27255807"></a>Huynh AL, Baker ST, Stewardson AJ, Johnson DF. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting. <i>Pharmacoepidemiol Drug Saf</i>. 2016;25(11):1274-1278. doi:10.1002/pds.4045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/27255807/pubmed" id="27255807" target="_blank">27255807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30144112">
<a name="30144112"></a>Imatoh T, Sai K, Takeyama M, et al. Identification of risk factors and development of detection algorithm for denosumab-induced hypocalcaemia. <i>J Clin Pharm Ther</i>. 2019;44(1):62-68. doi:10.1111/jcpt.12753<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/30144112/pubmed" id="30144112" target="_blank">30144112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.2011">
<a name="IOM.2011"></a>IOM (Institute of Medicine), <i>Dietary Reference Intakes for Calcium and Vitamin D,</i> Washington, DC: The National Academies Press, 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27980413">
<a name="27980413"></a>Ishikawa K, Nagai T, Sakamoto K, et al. High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. <i>Ther Clin Risk Manag</i>. 2016;12:1831-1840. doi:10.2147/TCRM.S123172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/27980413/pubmed" id="27980413" target="_blank">27980413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30519493">
<a name="30519493"></a>Jalleh R, Basu G, Le Leu R, Jesudason S. Denosumab-induced severe hypocalcaemia in chronic kidney disease.<i> Case Rep Nephrol.</i> 2018. doi:10.1155/2018/7384763<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/30519493/pubmed" id="30519493" target="_blank">30519493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21491487">
<a name="21491487"></a>Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. <i>J Bone Miner Res</i>. 2011;26(8):1829-1835. doi: 10.1002/jbmr.403.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/21491487/pubmed" id="21491487" target="_blank">21491487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32642421">
<a name="32642421"></a>Kaku T, Oh Y, Sato S, et al. Incidence of atypical femoral fractures in the treatment of bone metastasis: an alert report. <i>J Bone Oncol</i>. 2020;23:100301. doi:10.1016/j.jbo.2020.100301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/32642421/pubmed" id="32642421" target="_blank">32642421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18057140">
<a name="18057140"></a>Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. <i>Endocr Rev</i>. 2008;29(2):155-192. doi:10.1210/er.2007-0014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/18057140/pubmed" id="18057140" target="_blank">18057140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19594293">
<a name="19594293"></a>Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. <i>J Bone Miner Res.</i> 2010;25(1):72-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/19594293/pubmed" id="19594293" target="_blank">19594293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25414052">
<a name="25414052"></a>Khan AA, Morrison A, Hanley DA, et al; International Task Force on osteonecrosis of the jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. <i>J Bone Miner Res</i>. 2015;30(1):3-23. doi:10.1002/jbmr.2405<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/25414052/pubmed" id="25414052" target="_blank">25414052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30675420">
<a name="30675420"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). <i>Kidney Int Suppl (2011).</i> 2017;7(1):1-59. doi:10.1016/j.kisu.2017.04.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/30675420/pubmed" id="30675420" target="_blank">30675420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29076163">
<a name="29076163"></a>King BJ, Lehman JS, Sartori Valinotti JC. Denosumab-induced cutaneous hypersensitivity reaction with distinct clinical and histopathologic findings. <i>J Cutan Pathol</i>. 2018;45(2):156-158. doi:10.1111/cup.13070<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/29076163/pubmed" id="29076163" target="_blank">29076163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20306021">
<a name="20306021"></a>Kyrgidis A, Toulis KA. Denosumab-Related Osteonecrosis of the Jaws. <i>Osteoporos Int.</i> 2011;22(1):369-370.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/20306021/pubmed" id="20306021" target="_blank">20306021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27732330">
<a name="27732330"></a>Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B. Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. <i>J Clin Endocrinol Metab</i>. 2017;102(2):354-358. doi:10.1210/jc.2016-3170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/27732330/pubmed" id="27732330" target="_blank">27732330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32017154">
<a name="32017154"></a>Lau LH, Cliff ERS, Wong V, et al. Hypocalcaemia following denosumab in prostate cancer: a clinical review. <i>Clin Endocrinol (Oxf)</i>. 2020;92(6):495-502. doi:10.1111/cen.14169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/32017154/pubmed" id="32017154" target="_blank">32017154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17708711">
<a name="17708711"></a>Lewiecki EM, Miller PD, McClung MR, et al. Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD. <i>J Bone Miner Res.</i> 2007;22(12):1832-1841.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/17708711/pubmed" id="17708711" target="_blank">17708711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18927312">
<a name="18927312"></a>Lipton A, Steger GG, Figueroa J, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. <i>Clin Cancer Res.</i> 2008;14(20):6690-6696.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/18927312/pubmed" id="18927312" target="_blank">18927312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17785705">
<a name="17785705"></a>Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. <i>J Clin Oncol.</i> 2007;25(28):4431-4437.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/17785705/pubmed" id="17785705" target="_blank">17785705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27512722">
<a name="27512722"></a>Lyakhovitsky A, Oshinsky S, Gilboa S, Barzilai A. Alopecia areata after denosumab treatment for osteoporosis. <i>JAAD Case Rep</i>. 2016;2(4):298-300. doi:10.1016/j.jdcr.2016.06.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/27512722/pubmed" id="27512722" target="_blank">27512722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28379592">
<a name="28379592"></a>Malnick S, Maor Y, Melzer E, Ziv-Sokolowskaia NN, Neuman MG. Severe hepatocytotoxicity linked to denosumab. <i>Eur Rev Med Pharmacol Sci</i>. 2017;21(1 suppl):78-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/28379592/pubmed" id="28379592" target="_blank">28379592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28382583">
<a name="28382583"></a>Manzaneque A, Chaguaceda C, Mensa M, Bastida C, Creus-Baró N. Use and safety of denosumab in cancer patients. <i>Int J Clin Pharm</i>. 2017;39(3):522-526. doi:10.1007/s11096-017-0455-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/28382583/pubmed" id="28382583" target="_blank">28382583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30405927">
<a name="30405927"></a>Marlow CF, Sharma S, Babar F, Lin J. Severe hypocalcemia and hypomagnesemia with denosumab in advanced chronic kidney disease: case report and literature review.<i> Case Rep Oncol Med.</i> 2018. doi:10.1155/2018/2059364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/30405927/pubmed" id="30405927" target="_blank">30405927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29879891">
<a name="29879891"></a>Mazokopakis EE. Denosumab-induced normocalcemic hyperparathyroidism in a woman with postmenopausal osteoporosis and normal renal function. <i>Curr Drug Saf</i>. 2018;13(3):214-216. doi:10.2174/1574886313666180608080355<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/29879891/pubmed" id="29879891" target="_blank">29879891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16495394">
<a name="16495394"></a>McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. <i>N Engl J Med.</i> 2006;354(8):821-831.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/16495394/pubmed" id="16495394" target="_blank">16495394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27802096">
<a name="27802096"></a>Min BW, Koo KH, Park YS, et al. Scoring system for identifying impending complete fractures in incomplete atypical femoral fractures. <i>J Clin Endocrinol Metab</i>. 2017;102(2):545-550. doi:10.1210/jc.2016-2787<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/27802096/pubmed" id="27802096" target="_blank">27802096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30187112">
<a name="30187112"></a>Miyaoka D, Imanishi Y, Ohara M, et al. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency. <i>Osteoporos Int</i>. 2019;30(1):241-249. doi:10.1007/s00198-018-4688-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/30187112/pubmed" id="30187112" target="_blank">30187112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30870701">
<a name="30870701"></a>Mosch A, Ettl T, Mamilos A, et al. Physiological concentrations of denosumab enhance osteogenic differentiation in human mesenchymal stem cells of the jaw bone. <i>Arch Oral Biol</i>. 2019;101:23-29. doi:10.1016/j.archoralbio.2019.03.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/30870701/pubmed" id="30870701" target="_blank">30870701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NOF.2014">
<a name="NOF.2014"></a>National Osteoporosis Foundation (NOF). Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC, 2014. http://nof.org/files/nof/public/content/file/2791/upload/919.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31327935">
<a name="31327935"></a>Nguyen MTD, Sebag M, Harissi-Dagher M. Band keratopathy developing after denosumab injections. <i>Digit J Ophthalmol</i>. 2019;25(2):30-32. doi:10.5693/djo.02.2019.04.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/31327935/pubmed" id="31327935" target="_blank">31327935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34448749">
<a name="34448749"></a>North American Menopause Society. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. <i>Menopause</i>. 2021;28(9):973-997. doi:10.1097/GME.0000000000001831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/34448749/pubmed" id="34448749" target="_blank">34448749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23934346">
<a name="23934346"></a>Okada N, Kawazoe K, Teraoka K, et al. Identification of the risk factors associated with hypocalcemia induced by denosumab. <i>Biol Pharm Bull</i>. 2013;36(10):1622-1626. doi:10.1248/bpb.b13-00496.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/23934346/pubmed" id="23934346" target="_blank">23934346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32408510">
<a name="32408510"></a>Okuma S, Matsuda Y, Nariai Y, Karino M, Suzuki R, Kanno T. A retrospective observational study of risk factors for denosumab-related osteonecrosis of the jaw in patients with bone metastases from solid cancers. <i>Cancers (Basel)</i>. 2020;12(5):1209. doi:10.3390/cancers12051209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/32408510/pubmed" id="32408510" target="_blank">32408510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi: 10.1155/2012/985646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22113951">
<a name="22113951"></a>Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension. <i>J Bone Miner Res.</i> 2012;27(3):694-701.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/22113951/pubmed" id="22113951" target="_blank">22113951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25477311">
<a name="25477311"></a>Peer A, Khamaisi M. Diabetes as a risk factor for medication-related osteonecrosis of the jaw. <i>J Dent Res</i>. 2015;94(2):252-260. doi:10.1177/0022034514560768<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/25477311/pubmed" id="25477311" target="_blank">25477311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi: 10.1002/bdrb.20201.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28115267">
<a name="28115267"></a>Philipponnet C, Kemeny JL, Aniort J, Garrouste C, Heng AE. Immunoallergic interstitial nephritis secondary to denosumab. <i>Joint Bone Spine</i>. 2018;85(2):253-254. doi:10.1016/j.jbspin.2017.01.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/28115267/pubmed" id="28115267" target="_blank">28115267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22451554">
<a name="22451554"></a>Png MA, Koh JS, Goh SK, Fook-Chong S, Howe TS. Bisphosphonate-related femoral periosteal stress reactions: scoring system based on radiographic and MRI findings. <i>AJR Am J Roentgenol</i>. 2012;198(4):869-877. doi:10.2214/AJR.11.6794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/22451554/pubmed" id="22451554" target="_blank">22451554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Prolia.2020.03">
<a name="Prolia.2020.03"></a>Prolia (denosumab) [prescribing information]. Thousand Oaks, CA: Amgen Inc; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29429912">
<a name="29429912"></a>Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. <i>Lancet Oncol</i>. 2018;19(3):370-381. doi: 10.1016/S1470-2045(18)30072-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/29429912/pubmed" id="29429912" target="_blank">29429912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosen.1">
<a name="Rosen.1"></a>Rosen HN. Denosumab for osteoporosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 20, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosen.2">
<a name="Rosen.2"></a>Rosen HN, Drezner MK. Overview of the management of osteoporosis in postmenopausal women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 20, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25234529">
<a name="25234529"></a>Ruggiero SL, Dodson TB, Fantasia J, et al; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. <i>J Oral Maxillofac Surg</i>. 2014;72(10):1938-1956. doi: 10.1016/j.joms.2014.04.031.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/25234529/pubmed" id="25234529" target="_blank">25234529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21986094">
<a name="21986094"></a>Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. <i>Ann Oncol</i>. 2012;23(5):1341-1347. doi:10.1093/annonc/mdr435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/21986094/pubmed" id="21986094" target="_blank">21986094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29631782">
<a name="29631782"></a>Saag KG, Wagman RB, Geusens P et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. <i>Lancet Diabetes Endocrinol</i>. 2018;6(6):445-454.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/29631782/pubmed" id="29631782" target="_blank">29631782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30826782">
<a name="30826782"></a>Sanchez A, Lozier M, Adkinson BC, Ilaiwy A. c-ANCA vasculitis after initiation of denosumab. <i>BMJ Case Rep</i>. 2019;12(3):e228336. doi:10.1136/bcr-2018-228336<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/30826782/pubmed" id="30826782" target="_blank">30826782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31990618">
<a name="31990618"></a>Saylor PJ, Rumble RB, Tagawa S, et al. Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a Cancer Care Ontario guideline. <i>J Clin Oncol</i>. 2020;38(15):1736-1743. doi:10.1200/JCO.19.03148<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/31990618/pubmed" id="31990618" target="_blank">31990618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23154554">
<a name="23154554"></a>Scagliotti GV, Hirsh V, Siena S, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: Subgroup analysis from a randomized phase 3 study. <i>J Thorac Oncol</i>, 2012;7(12):1823-1829.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/23154554/pubmed" id="23154554" target="_blank">23154554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26501556">
<a name="26501556"></a>Selga J, Nuñez JH, Minguell J, Lalanza M, Garrido M. Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review. <i>Osteoporos Int</i>. 2016;27(2):827-832. doi:10.1007/s00198-015-3355-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/26501556/pubmed" id="26501556" target="_blank">26501556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shane.2022">
<a name="Shane.2022"></a>Shane E. Treatment of hypercalcemia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed August 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23712442">
<a name="23712442"></a>Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. <i>J Bone Miner Res</i>. 2014;29(1):1-23. doi:10.1002/jbmr.1998<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/23712442/pubmed" id="23712442" target="_blank">23712442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31532726">
<a name="31532726"></a>Shapiro CL, Van Poznak C, Lacchetti C, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. <i>J Clin Oncol</i>. 2019;37(31):2916-2946. doi: 10.1200/JCO.19.01696.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/31532726/pubmed" id="31532726" target="_blank">31532726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19671656">
<a name="19671656"></a>Smith MR, Egerdie B, Hernández Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. <i>N Engl J Med.</i> 2009;361(8):745-755.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/19671656/pubmed" id="19671656" target="_blank">19671656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22093187">
<a name="22093187"></a>Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, pandomised, placebo-controlled trial. <i>Lancet.</i> 2012;379(9810):39-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/22093187/pubmed" id="22093187" target="_blank">22093187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26447647">
<a name="26447647"></a>Sohn W, Lee E, Kankam MK, et al. An open-label study in healthy men to evaluate the risk of seminal fluid transmission of denosumab to pregnant partners. <i>Br J Clin Pharmacol</i>. 2016;81(2):362-369. doi: 10.1111/bcp.12798.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/26447647/pubmed" id="26447647" target="_blank">26447647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29951870">
<a name="29951870"></a>Starr J, Tay YKD, Shane E. Current understanding of epidemiology, pathophysiology, and management of atypical femur fractures. <i>Curr Osteoporos Rep</i>. 2018;16(4):519-529. doi:10.1007/s11914-018-0464-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/29951870/pubmed" id="29951870" target="_blank">29951870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26335402">
<a name="26335402"></a>Stopeck AT, Fizazi K, Body JJ, et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. <i>Support Care Cancer</i>. 2016;24(1):447-445. doi: 10.1007/s00520-015-2904-5 Erratum in: Support Care Cancer. 2015 Oct 19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/26335402/pubmed" id="26335402" target="_blank">26335402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21060033">
<a name="21060033"></a>Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. <i>J Clin Oncol.</i> 2010;28(35):5132-5139.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/21060033/pubmed" id="21060033" target="_blank">21060033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31640606">
<a name="31640606"></a>Takahashi M, Ozaki Y, Kizawa R, et al. Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review. <i>BMC Cancer</i>. 2019;19(1):980. doi:10.1186/s12885-019-6236-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/31640606/pubmed" id="31640606" target="_blank">31640606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19836866">
<a name="19836866"></a>Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. <i>Br J Oral Maxillofac Surg. </i>2010;48(3):221-223.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/19836866/pubmed" id="19836866" target="_blank">19836866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20149736">
<a name="20149736"></a>Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: An open-label, phase 2 study. <i>Lancet Oncol.</i> 2010;11(3):275-280.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/20149736/pubmed" id="20149736" target="_blank">20149736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29713798">
<a name="29713798"></a>Thongprayoon C, Acharya P, Acharya C, et al. Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies. <i>Osteoporos Int.</i> 2018;29(8):1737-1745. doi:10.1007/s00198-018-4533-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/29713798/pubmed" id="29713798" target="_blank">29713798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28789921">
<a name="28789921"></a>Tsourdi E, Langdahl B, Cohen-Solal M, et al. Discontinuation of denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. <i>Bone</i>. 2017;105:11-17. doi:10.1016/j.bone.2017.08.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/28789921/pubmed" id="28789921" target="_blank">28789921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33103722">
<a name="33103722"></a>Tsourdi E, Zillikens MC, Meier C, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. <i>J Clin Endocrinol Metab</i>. Published online October 26, 2020. doi:10.1210/clinem/dgaa756<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/33103722/pubmed" id="33103722" target="_blank">33103722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31193884">
<a name="31193884"></a>Tyan A, Patel SP, Block S, Hughes T, McCowen KC. Rebound vertebral fractures in a patient with lung cancer after oncology-dose denosumab discontinuation: a cautionary tale. <i>Mayo Clin Proc Innov Qual Outcomes</i>. 2019;3(2):235-237. doi:10.1016/j.mayocpiqo.2019.02.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/31193884/pubmed" id="31193884" target="_blank">31193884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26205395">
<a name="26205395"></a>Ueda T, Morioka H, Nishida Y, et al. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial. <i>Ann Oncol</i>. 2015;26(10):2149-2154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/26205395/pubmed" id="26205395" target="_blank">26205395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26466702">
<a name="26466702"></a>Ueki K, Yamada S, Tsuchimoto A, et al. Rapid progression of vascular and soft tissue calcification while being managed for severe and persistent hypocalcemia induced by denosumab treatment in a patient with multiple myeloma and chronic kidney disease. <i>Intern Med.</i> 2015;54(20):2637-2642. doi:10.2169/internalmedicine.54.4946<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/26466702/pubmed" id="26466702" target="_blank">26466702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28963584">
<a name="28963584"></a>van Cann T, Loyson T, Verbiest A, et al. Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. <i>Support Care Cancer</i>. 2018;26(3):869-878. doi:10.1007/s00520-017-3903-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/28963584/pubmed" id="28963584" target="_blank">28963584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29035643">
<a name="29035643"></a>Van Poznak C, Somerfield MR, Barlow WE, et al. Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused guideline update.<i> J Clin Oncol</i>. 2017;35(35):3978-3986. doi: 10.1200/JCO.2017.75.4614.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/29035643/pubmed" id="29035643" target="_blank">29035643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21343561">
<a name="21343561"></a>Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. <i>J Clin Oncol.</i> 2011;29(9):1221-1227.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/21343561/pubmed" id="21343561" target="_blank">21343561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22675062">
<a name="22675062"></a>Watts NB, Adler RA, Bilezikian JP, et al; Endocrine Society. Osteoporosis in men: An Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2012;97(6):1802-1822.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/22675062/pubmed" id="22675062" target="_blank">22675062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21892677">
<a name="21892677"></a>Watts NB, Roux C, Modlin JF, et al. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? <i>Osteoporos Int</i>. 2012;23(1):327-337. doi:10.1007/s00198-011-1755-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/21892677/pubmed" id="21892677" target="_blank">21892677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xgeva.2020.02">
<a name="Xgeva.2020.02"></a>Xgeva (denosumab) [prescribing information]. Thousand Oaks, CA: Amgen Inc; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xgeva.2020.06">
<a name="Xgeva.2020.06"></a>Xgeva (denosumab) [prescribing information]. Thousand Oaks, CA: Amgen Inc; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28275116">
<a name="28275116"></a>Yang SP, Kim TW, Boland PJ, Farooki A. Retrospective review of atypical femoral fracture in metastatic bone disease patients receiving denosumab therapy. <i>Oncologist</i>. 2017;22(4):438-444. doi:10.1634/theoncologist.2016-0192<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/28275116/pubmed" id="28275116" target="_blank">28275116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31329513">
<a name="31329513"></a>Yarom N, Shapiro CL, Peterson DE, et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. <i>J Clin Oncol</i>. 2019;37(25):2270-2290. doi:10.1200/JCO.19.01186<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/denosumab-drug-information/abstract-text/31329513/pubmed" id="31329513" target="_blank">31329513</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 15575 Version 256.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
